Vol 8, No 4 (2017)
- Year: 2017
- Articles: 6
- URL: https://journals.rcsi.science/2221-7185/issue/view/2717
- DOI: https://doi.org/10.26442/CS.201784
Articles
The role of galectin-3 in the diagnosis and control of the effectiveness of pharmacotherapy of chronic heart failure
Abstract
Relevance. At present, it is urgent to develop new biomarkers that can serve as a tool for early diagnosis of the disease in order to select pharmacotherapy and further monitor its effectiveness. The goal is to evaluate the clinical value of the definition of galectin-3 in patients with chronic heart failure (CHF). Materials and methods. The study included 53 patients (31 women, 22 men) with CHF II-III functional class (FC) of the New York Heart Association (NYHA). The mean age of the patients was 71 years (95% confidence interval 68.99-74.37). A group of patients with NYHA FCh II CHF made up 14 people, a group of patients with NYHA-39 CHF III FC. The median of the initial level of the N-terminal brain natriuretic peptide (NT-proBNP) was 65.7 pmol/L, the median of the initial level of galectin-3 - 8.37 pmol/l. Results. The relationship of increased level of galectin-3 with reduced ejection fraction,% (r=-0.26, p=0.04), increased creatinine level (r=0.26, p=0.04) and increased level of NT-proBNP plasma (r=0.3, p=0.02). With other clinical indicators, such as systolic and diastolic blood pressure, heart rate, body mass index, 6-minute walk test, left ventricular mass index, glucose level, total cholesterol, glomerular filtration rate, no statistically significant association was found. A moderate correlation was obtained between the levels of NT-proBNP and galectin-3 plasma (r=0.3, p=0.02). Reduction in the level of galectin-3 after the treatment was detected in 84.3% of patients. The conclusion. Galectin-3 can serve as an additional diagnostic biomarker of CHF.
CardioSomatics. 2017;8(4):5-10
5-10
Acute kidney injury worsens outcomes in acute decompensation of chronic heart failure
Abstract
Acute kidney injury was 33.6% of patients had acute decompensation of chronic heart failure. This complication has increased the number of cardiovascular diseases, relapses of chronic heart failure decompensation and mortality during the next 12 months.
CardioSomatics. 2017;8(4):11-14
11-14
High-intensity therapy: rationale, indications and safety issues. Prospects of rosuvastatin in clinical practice
Abstract
The review is devoted to the problem of high-intensity therapy. Evidence of the effectiveness of statin prescribing in high-intensity mode is presented to patients with very high cardiovascular risk. Indications for such therapy and its principles are indicated. The issues of tolerability and safety of high-intensity therapy are considered.
CardioSomatics. 2017;8(4):15-24
15-24
Basic principles of antiplatelet therapy from the perspective of new recommendations
Abstract
In the presented review, some of the main points of the new European recommendations on the use of double antiplatelet therapy (DAT) and triple antithrombotic therapy in patients with coronary heart disease (CHD) with different approaches to its treatment (conservative, invasive and surgical) are outlined. The positions of acetylsalicylic acid (ASA) are designated as the primary basis of a prophylactic antiplatelet strategy. Attention is paid to a new risk stratification for the calculation of the duration of DAT, recommendations for the proper choice of receptor inhibitors for adenosine diphosphate type P2Y12, for switching between oral inhibitors of P2Y12 and for the duration of DAT in different forms of CHD. The review discusses adherence to therapy with ASA and DAT.
CardioSomatics. 2017;8(4):26-35
26-35
36-40
42-46